Regeneron acquires 23andMe's genetics services for (Dollar) 256 million * Customer privacy safeguards will remain in place under a court-monitored //process * Lemonaid Health excluded from the deal ...

Biotechbedrijf Regeneron Pharmaceuticals neemt voor 256 miljoen dollar de kernactiviteiten en data van het failliete 23andMe over. Misschien inclusief jouw dna? Het Amerikaanse 23andMe, dat zich ...

Het Amerikaanse farmabedrijf Regeneron heeft het failliete dna-testbedrijf 23andMe, inclusief de persoonlijke en genetische data van vijftien miljoen gebruikers, voor een bedrag van 256 miljoen ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

States sue to halt Regeneron's 23andMe acquisition, citing privacy concerns over user DNA data, as a court-ordered report on ...

In a landmark move within the biotech industry, Regeneron Pharmaceuticals has announced its acquisition of 23andMe for $256 million. This deal, emerging from 23andMe's bankruptcy proceedings ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business. With this deal, Regeneron will gain access to a large database of consumer genetic information.

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations. Regeneron Pharmaceuticals has announced an agreement to acquire all assets of 23andMe for $256 ...

Ahead of a sale, only 15% of 23andMe's user base has deleted accounts. Do people not care, or are they just unaware? For ...

A biotech future built on data: Regeneron’s acquisition of 23andMe blurs the line between pharmaceutical innovation and genetic surveillance. Unsplash+ “We are pleased to have reached a ...